- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.08. | Braveheart Bio's $382M IPO for Heart Drug Leads a Big Week for Biotech IPOs | 3 | MedCity News | ||
| 07.08. | Braveheart Bio schließt Börsengang an der NASDAQ mit 439,9 Mio. US-Dollar ab | 1 | Investing.com Deutsch | ||
| 07.08. | Braveheart Bio closes $439.9 million IPO on Nasdaq | 2 | Investing.com | ||
| 07.08. | Braveheart Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.08. | Braveheart Bio, Inc.: Braveheart Bio Announces Closing of Upsized Initial Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares | 276 | GlobeNewswire (Europe) | SAN FRANCISCO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy... ► Artikel lesen | |
| 06.08. | Braveheart Bio charges past expectations with $382.5M IPO to fund cardio drug from Hengrui | 1 | FierceBiotech | ||
| 06.08. | Cardiovascular diseases biotech Braveheart Bio prices upsized IPO at $18, above the range | 1 | Renaissance Capital | ||
| BRAVEHEART BIO Aktie jetzt für 0€ handeln | |||||
| 06.08. | Braveheart Bio prices $382.5M IPO at $18 per share | 1 | Investing.com | ||
| 06.08. | Braveheart Bio, Inc.: Braveheart Bio Announces Pricing of Upsized Initial Public Offering | 304 | GlobeNewswire (Europe) | SAN FRANCISCO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy... ► Artikel lesen | |
| 03.08. | Braveheart Bio, Inc. - 8-A12B, Registration of securities | 1 | SEC Filings | ||
| 30.07. | Braveheart Bio, Attovia seek $275M and $182M in U.S. IPOs | 1 | Seeking Alpha | ||
| 30.07. | Attovia, Braveheart Bio and Vogenx seek more than $500M across trio of IPOs | 1 | FierceBiotech | ||
| 30.07. | Cardiovascular diseases biotech Braveheart Bio sets terms for $300 million IPO | 1 | Renaissance Capital | ||
| 30.07. | Braveheart Bio, Inc. - S-1/A, General form for registration of securities | 3 | SEC Filings | ||
| 16.07. | Two more biotechs, Attovia and Braveheart Bio, join the IPO line | 1 | pharmaphorum | ||
| 15.07. | Braveheart Bio aims for freedom with IPO to support Hengrui-licensed cardio asset | 13 | FierceBiotech | ||
| 15.07. | Braveheart Bio, Attovia, Apnimed join gene therapy firm Scribe Therapeutics in July IPO rush | 3 | Seeking Alpha | ||
| 15.07. | Braveheart Bio, Attovia join next wave of biotech IPOs | 1 | BioPharma Dive | ||
| 15.07. | Cardiovascular diseases biotech Braveheart Bio files for a $100 million IPO | 1 | Renaissance Capital | ||
| 14.07. | Braveheart Bio, Inc. - S-1, General form for registration of securities | 1 | SEC Filings |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SUMMIT THERAPEUTICS | 13,730 | 0,00 % | Summit Therapeutics Partner Highlights Positive Interim Data Milestone for Lead Cancer Therapy | ||
| BIONTECH | 88,30 | +0,11 % | BioNTech Aktie: Im Rausch der Moderna-Euphorie - Doch wie lange hält die Party an? | © Foto: von fernando zhiminaicela auf Pixabay (Symbolbild)Fast 30 Prozent in einer einzigen Woche. Das ist lange her, dass sowas bei BioNTech vorkam. Zuletzt wohl zu Pandemie-Zeiten ging es mal so zur... ► Artikel lesen | |
| QIAGEN | 37,590 | -0,42 % | DAX Verlierer: Qiagen Aktie | Kursentwicklung und Chartanalyse | ||
| ARCUTIS BIOTHERAPEUTICS | 23,780 | 0,00 % | Here's Why You Should Add ARQT Stock to Your Portfolio Now | ||
| HARMONY BIOSCIENCES | 39,210 | 0,00 % | Wolfe Research initiates Harmony Biosciences stock at Outperform | ||
| ERASCA | 18,040 | +0,06 % | Erasca, Inc. - 8-K, Current Report | ||
| APOGEE THERAPEUTICS | 134,97 | 0,00 % | Apogee Therapeutics: Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates | AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive... ► Artikel lesen | |
| COGENT BIOSCIENCES | 34,670 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| MODERNA | 119,06 | -0,03 % | Moderna Aktie: Was für ein Wahnsinn bei Moderna! Kippt aber jetzt die Stimmung?! | © Foto: Finanznachrichten (Symbolbild wurde mit KI erstellt)Erst ein Kurssprung wie ihn kaum eine Aktie je erlebt hat, dann der schnelle Absturz, aber kommt jetzt wieder eine Erholung? Moderna sorgt... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 345,01 | +0,08 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| RELAY THERAPEUTICS | 18,760 | -0,05 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates | Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine- sensitive patients expected to initiate in early 2027, subject to regulatory... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 78,08 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $980 - $995 million -- KPL-387... ► Artikel lesen | |
| VERA THERAPEUTICS | 34,210 | +0,06 % | Weekly Buzz: Johnson & Johnson, Vera Therapeutics Get FDA Nod; Vertex Pharmaceuticals Snaps Up Crinetics Pharmaceuticals; Satellos Bioscience Aces DMD Trial; Ionis Pharmaceuticals Misses Key Goal | NEW BRUNSWICK (dpa-AFX) - This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech... ► Artikel lesen | |
| TANGO THERAPEUTICS | 23,370 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 5,770 | 0,00 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett syndrome; expect to report topline data from 6- month interim analysis and FDA feedback on the BLA... ► Artikel lesen |
Das Unternehmen BRAVEHEART BIO INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,060 (-0,22 %) liegt der Kurs bei 27,380 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BRAVEHEART BIO INC finden Sie auf Wallstreet Online.